Review Times For New Drugs And Submission Delays Among The FDA And 4 International Regulators, 2014–22
Health Affairs · 01.02.2026 · 45 (2) · 184-192
DOI: 10.1377/hlthaff.2025.00595 ↗Kurz gefasst
Fachartikel in der Zeitschrift Health Affairs, erschienen am 01.02.2026. Verfasst von Irene Papanicolas und 5 weiteren Autor:innen. Beteiligte Einrichtung: Irene Papanicolas (irene_papanicolas@brown.edu), Brown University, Providence, Rhode Island. Hauptthemen laut MEDLINE: Drug Approval, United States Food and Drug Administration. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 25 Literaturangaben.
Abstract (Originalsprache)
Factors influencing the timing of regulatory submission for new drugs across countries are poorly understood. We identified all new drugs approved by the Food and Drug Administration (FDA) or European Medicines Agency (EMA) during the period 2014-18 and tracked their regulatory submissions to the US, the European Union, Canada, Japan, and Australia through 2022. We assessed whether disease area, orphan status, therapeutic value, market size, and launch price were associated with submission delays. The FDA received the highest proportion of first submissions (70 percent). Median submission delays ranged from zero months (FDA) to 18.5 months (Australia). The range of median regulatory review times was small (9.2-14.1 months) compared with the range of median submission delays. Drugs with moderate-to-high therapeutic value were associated with a six-month earlier submission time compared to drugs with low therapeutic value, on average. Higher-price drugs were associated with earlier submission, on average. Overall, cross-national differences in drug availability largely reflected differences in submission, not regulatory review, times. Although the US had greater and faster availability of novel therapeutics, the difference was smaller for drugs that offered moderate-to-high therapeutic value.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Autor:innen und Institutionen
- Irene Papanicolas (irene_papanicolas@brown.edu), Brown University, Providence, Rhode Island.
- Olivier J. Wouters, Brown University.
- Tania Sawaya, Brown University.
- Jihye Han, Vanderbilt University, Nashville, Tennessee.
- Jinru Wei, Brown University.
- Huseyin Naci, London School of Economics and Political Science, London, United Kingdom.
Zitieren
APA
Papanicolas, I., Wouters, O. J., Sawaya, T., Han, J., Wei, J., & Naci, H. (2026). Review Times For New Drugs And Submission Delays Among The FDA And 4 International Regulators, 2014–22. Health Affairs, 45(2), 184-192. https://doi.org/10.1377/hlthaff.2025.00595
Vancouver
Papanicolas I, Wouters OJ, Sawaya T, Han J, Wei J, Naci H. Review Times For New Drugs And Submission Delays Among The FDA And 4 International Regulators, 2014–22. Health Affairs. 2026;45(2):184-192. doi:10.1377/hlthaff.2025.00595
BibTeX
@article{Papanicolas2026,
author = {Papanicolas, Irene and Wouters, Olivier J and Sawaya, Tania and Han, Jihye and Wei, Jinru and Naci, Huseyin},
title = {Review Times For New Drugs And Submission Delays Among The FDA And 4 International Regulators, 2014–22},
journal = {Health Affairs},
year = {2026},
volume = {45},
number = {2},
pages = {184--192},
doi = {10.1377/hlthaff.2025.00595}
}
EUVIMED